Syndax Pharmaceuticals, Inc. (SNDX)

USD 13.24

(-2.86%)

Market Cap (In USD)

1.13 Billion

Revenue (In USD)

-

Net Income (In USD)

-209.36 Million

Avg. Volume

1.05 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
13.08-25.34
PE
-
EPS
-
Beta Value
0.917
ISIN
US87164F1057
CUSIP
87164F105
CIK
1395937
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Michael A. Metzger M.B.A.
Employee Count
-
Website
https://www.syndax.com
Ipo Date
2016-03-02
Details
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

More Stocks